UCB S.A. UNSP.ADR 1/2 - Asset Resilience Ratio

Latest as of December 2025: 1.08%

UCB S.A. UNSP.ADR 1/2 (UNC0) has an Asset Resilience Ratio of 1.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore UNC0 asset base for the complete picture of this company's asset base.

Liquid Assets

€196.00 Million

≈ $229.14 Million USD Cash + Short-term Investments

Total Assets

€18.16 Billion

≈ $21.23 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how UCB S.A. UNSP.ADR 1/2's Asset Resilience Ratio has changed over time. See UNC0 equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down UCB S.A. UNSP.ADR 1/2's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is UCB S.A. UNSP.ADR 1/2 worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€196.00 Million	1.08%
Total Liquid Assets	€196.00 Million	1.08%

Asset Resilience Insights

Limited Liquidity: UCB S.A. UNSP.ADR 1/2 maintains only 1.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

UCB S.A. UNSP.ADR 1/2 Industry Peers by Asset Resilience Ratio

Compare UCB S.A. UNSP.ADR 1/2's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Hyundai Bioscience Co. Ltd KQ:048410	Biotechnology	13.57%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	82.25%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for UCB S.A. UNSP.ADR 1/2 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for UCB S.A. UNSP.ADR 1/2.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.08%	€196.00 Million ≈ $229.14 Million	€18.16 Billion ≈ $21.23 Billion	+0.02pp
2024-12-31	1.06%	€184.00 Million ≈ $215.12 Million	€17.35 Billion ≈ $20.28 Billion	-0.19pp
2023-12-31	1.25%	€195.00 Million ≈ $227.98 Million	€15.54 Billion ≈ $18.17 Billion	-0.28pp
2022-12-31	1.53%	€243.00 Million ≈ $284.09 Million	€15.87 Billion ≈ $18.55 Billion	+0.04pp
2021-12-31	1.49%	€212.00 Million ≈ $247.85 Million	€14.21 Billion ≈ $16.61 Billion	--

pp = percentage points

About UCB S.A. UNSP.ADR 1/2

F:UNC0 Germany Biotechnology

Market Cap

$53.31 Billion

€45.60 Billion EUR

Market Cap Rank

#606 Global

#124 in Germany

Share Price

€120.00

Change (1 day)

-2.44%

52-Week Range

€71.50 - €142.00

All Time High

€142.00